📊 EW Key Takeaways
Is Edwards Lifesciences Corp (EW) a Good Investment?
Despite strong balance sheet fundamentals and 78% gross margins, Edwards Lifesciences exhibits critical warning signs: negative free cash flow of -21.1M, EPS declining 73.7% YoY despite massive revenue growth, and operating cash flow of only 43.8M against 380.7M net income indicating severe cash conversion issues. The 29843% revenue growth suggests non-organic expansion (acquisition) that is not translating to shareholder value, evidenced by deteriorating ROE (3.7%) and ROA (2.9%).
Edwards Lifesciences shows high-quality fundamentals with strong gross margins, solid operating profitability, robust free cash flow generation, and a very conservative balance sheet. Liquidity is excellent and leverage is low, which supports resilience and strategic flexibility. However, the extreme revenue growth figure and sharp EPS decline alongside flat net income suggest comparability or one-time-item distortion, so the underlying growth trend needs confirmation before a more aggressive rating is justified.
Why Buy Edwards Lifesciences Corp Stock? EW Key Strengths
- Exceptional balance sheet with 0.06x debt/equity ratio and 2.4B cash position
- Strong profitability margins: 78% gross margin, 29% operating margin, 23.1% net margin
- Excellent liquidity with 4.42x current ratio and 27.1x interest coverage ratio
- High profitability with 78.0% gross margin, 20.8% operating margin, and 17.7% net margin
- Strong financial health driven by $2.94B cash, 3.72x current ratio, and very low 0.06x debt-to-equity
- Healthy cash generation with $1.33B free cash flow and a 22.0% FCF margin
EW Stock Risks: Edwards Lifesciences Corp Investment Risks
- Negative free cash flow of -21.1M despite positive net income indicates poor earnings quality and working capital deterioration
- Diluted EPS collapsed 73.7% YoY despite 29843% revenue growth, signaling severe share dilution or non-accretive M&A activity
- Abysmal capital efficiency: ROE of 3.7% and ROA of 2.9% indicate deployed capital is generating minimal returns
- Revenue growth of +29843.1% appears abnormal and may reflect reporting distortion or a non-recurring event
- Diluted EPS fell 73.7% year over year despite stable net income, raising questions about earnings quality or share count effects
- ROE of 10.4% is respectable but not exceptional relative to the company’s large equity base
Key Metrics to Watch
- Free cash flow conversion and operating cash flow sustainability
- Organic revenue growth rate excluding acquisition impact
- Earnings per share trajectory and share dilution patterns
- Normalized organic revenue growth and segment-level sales trends
- Diluted EPS progression relative to net income and free cash flow
Edwards Lifesciences Corp (EW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.42x current ratio provides a solid financial cushion.
EW Profit Margin, ROE & Profitability Analysis
EW vs Healthcare Sector: How Edwards Lifesciences Corp Compares
How Edwards Lifesciences Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Edwards Lifesciences Corp Stock Overvalued? EW Valuation Analysis 2026
Based on fundamental analysis, Edwards Lifesciences Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Edwards Lifesciences Corp Balance Sheet: EW Debt, Cash & Liquidity
EW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Edwards Lifesciences Corp's revenue has grown significantly by 16% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.30 reflects profitable operations.
EW Revenue Growth, EPS Growth & YoY Performance
EW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.4B | $358.0M | $0.61 |
| Q3 2025 | $1.4B | $291.1M | $0.50 |
| Q2 2025 | $1.4B | $333.2M | $0.56 |
| Q1 2025 | $1.3B | $351.9M | $0.58 |
| Q3 2024 | $1.2B | $384.9M | $0.63 |
| Q2 2024 | $1.3B | $307.1M | $0.50 |
| Q1 2024 | $1.5B | $340.5M | $0.56 |
| Q3 2023 | $1.3B | $343.5M | $0.55 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Edwards Lifesciences Corp Dividends, Buybacks & Capital Allocation
EW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Edwards Lifesciences Corp (CIK: 0001099800)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EW
What is the AI rating for EW?
Edwards Lifesciences Corp (EW) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EW's key strengths?
Claude: Exceptional balance sheet with 0.06x debt/equity ratio and 2.4B cash position. Strong profitability margins: 78% gross margin, 29% operating margin, 23.1% net margin. ChatGPT: High profitability with 78.0% gross margin, 20.8% operating margin, and 17.7% net margin. Strong financial health driven by $2.94B cash, 3.72x current ratio, and very low 0.06x debt-to-equity.
What are the risks of investing in EW?
Claude: Negative free cash flow of -21.1M despite positive net income indicates poor earnings quality and working capital deterioration. Diluted EPS collapsed 73.7% YoY despite 29843% revenue growth, signaling severe share dilution or non-accretive M&A activity. ChatGPT: Revenue growth of +29843.1% appears abnormal and may reflect reporting distortion or a non-recurring event. Diluted EPS fell 73.7% year over year despite stable net income, raising questions about earnings quality or share count effects.
What is EW's revenue and growth?
Edwards Lifesciences Corp reported revenue of $1.6B.
Does EW pay dividends?
Edwards Lifesciences Corp does not currently pay dividends.
Where can I find EW SEC filings?
Official SEC filings for Edwards Lifesciences Corp (CIK: 0001099800) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EW's EPS?
Edwards Lifesciences Corp has a diluted EPS of $0.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EW a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Edwards Lifesciences Corp has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EW stock overvalued or undervalued?
Valuation metrics for EW: ROE of 3.7% (sector avg: 15%), net margin of 23.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EW stock in 2026?
Our dual AI analysis gives Edwards Lifesciences Corp a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is EW's free cash flow?
Edwards Lifesciences Corp's operating cash flow is $43.8M, with capital expenditures of $64.9M. FCF margin is -1.3%.
How does EW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 23.1% (avg: 12%), ROE 3.7% (avg: 15%), current ratio 4.42 (avg: 2).